Perjeta (pertuzumab)

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

HER2 dimerization inhibitor

QL1209 (pertuzumab biosimilar) (1)

BCD-178 (pertuzumab biosimilar) (0)

HS627 (pertuzumab biosimilar) (0)

P013 (pertuzumab biosimilar) (0)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

QL1209 (pertuzumab biosimilar) (1)

(0)

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1
HER-2 amplification	Colorectal Cancer	HER-2 amplification	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab Sensitive: A2 - Guideline pertuzumab Sensitive : A2	pertuzumab Sensitive: A2 - Guideline pertuzumab Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HER-2 positive	Biliary Tract Cancer	HER-2 positive	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab + pertuzumab Sensitive: B - Late Trials trastuzumab + pertuzumab Sensitive : B	trastuzumab + pertuzumab Sensitive: B - Late Trials trastuzumab + pertuzumab Sensitive : B
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	trastuzumab + pertuzumab Sensitive: B - Late Trials trastuzumab + pertuzumab Sensitive : B	trastuzumab + pertuzumab Sensitive: B - Late Trials trastuzumab + pertuzumab Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab + pertuzumab + alpelisib Sensitive: B - Late Trials trastuzumab + pertuzumab + alpelisib Sensitive : B	trastuzumab + pertuzumab + alpelisib Sensitive: B - Late Trials trastuzumab + pertuzumab + alpelisib Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Resistant: B - Late Trials pertuzumab + ado-trastuzumab emtansine Resistant : B	pertuzumab + ado-trastuzumab emtansine Resistant: B - Late Trials pertuzumab + ado-trastuzumab emtansine Resistant : B
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	trastuzumab + pertuzumab Sensitive: C1 - Off-label trastuzumab + pertuzumab Sensitive : C1	trastuzumab + pertuzumab Sensitive: C1 - Off-label trastuzumab + pertuzumab Sensitive : C1
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 overexpression	Breast Cancer	HER-2 overexpression	Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 amplification	Prostate Cancer	HER-2 amplification	Prostate Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 amplification	Ovarian Cancer	HER-2 amplification	Ovarian Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 overexpression	Ovarian Cancer	HER-2 overexpression	Ovarian Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 amplification	Pancreatic Cancer	HER-2 amplification	Pancreatic Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 amplification	Salivary Gland Cancer	HER-2 amplification	Salivary Gland Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 overexpression	Colorectal Cancer	HER-2 overexpression	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2

Perjeta (pertuzumab)

Associations
(102)

Associations
(102)

Perjeta (pertuzumab)

Associations(102)

Associations(102)

Associations
(102)

Associations
(102)